NCT05834582 - Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

Fluzoparib+Paclitaxel

Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy

DRUG

Epirubicin+Cyclophosphamide

Trial Locations (1)

RECRUITING

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER